Pharmacogenomics of Anti-TNF (Anti-tumor Necrosis Factor) Treatment in Patients With Rheumatoid Arthritis
Recruitment status was: Recruiting
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Pharmacogenomics of Anti-TNF Treatment in Patients With Rheumatoid Arthritis|
|Study Start Date:||May 2004|
|Estimated Study Completion Date:||April 2014|
|Estimated Primary Completion Date:||November 2013 (Final data collection date for primary outcome measure)|
Rheumatoid Arthritis (RA) is a severe inflammatory disease and genetic factors are known to play an important role in its pathogenesis. Genetic factors are also involved in determining the prognosis of RA. Identifying the genetic factors that predispose to mild or aggressive RA is not easy and up to now only a few of these factors -like certain HLA-DR species- are known.
The Rheumatology department of the Radboud University Nijmegen Medical Centre (RUNMC) has collected a unique inception cohort of over 500 patients with RA, that have been followed from an early stage of disease for up to 10 years with detailed measurements of disease activity, joint damage and other characteristics of disease progression.
In this project we use this patient group to study polymorphisms in a large battery of genes for their effect on RA disease activity/progression.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00321217
|Arnhem, Netherlands, 6800 TA|
|Radboud University Nijmegen Medical Centre|
|Nijmegen, Netherlands, 6500 HB|
|Nijmegen, Netherlands, 6522 JV|
|Principal Investigator:||M. J. Coenen, PhD||Radboud University|